Priyankan Raj
About Priyankan Raj
Data last updated:
Priyankan Raj is a Director at Danforth Remedies Private Limited (since 2022). The companies operate in Trading and Pharma. Danforth Remedies Private Limited reported revenue of ₹3.8 Lakh (FY 2025). Earlier, Priyankan Raj was a Director at Eart Pharmaceuticals Private Limited (2021–2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Danforth Remedies Private Limited U51909DL2022PTC405948 | Director | 17 Oct 2022 | 2022 | ₹3.8 Lakh (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Eart Pharmaceuticals Private Limited U24290DL2021PTC378972 | Director | 22 Mar 2021 | 2021 | ₹11.5 Lakh (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Priyankan Raj
| Name | DIN | Company | Designation |
|---|---|---|---|
| Gautami Kumari | 09767498 | Danforth Remedies Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Priyankan Raj
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Priyankan Raj
Priyankan Raj currently holds 1 directorship: Danforth Remedies Private Limited (Director, since 17 Oct 2022, revenue ₹3.8 Lakh (FY 2025)).
Priyankan Raj was first appointed on 22 Mar 2021 as Director at Eart Pharmaceuticals Private Limited. The most recent appointment on record is 17 Oct 2022 at Danforth Remedies Private Limited.
Priyankan Raj held 1 earlier board appointment: Eart Pharmaceuticals Private Limited (Director, 22 Mar 2021 to 17 Aug 2022).
The current boards of Priyankan Raj's companies include Gautami Kumari (Danforth Remedies Private Limited).